$KVUE · Kenvue Inc.
Kenvue filed its 10-Q for the quarter ended September 27, 2026. Q3 net sales rose 3.2% YoY to $3.886B, with organic growth of 2.9% driven by volume (+1.6%) and price/mix (+1.3%). Operating income jumped 12.2% to $706M as restructuring expenses fell 60.7% to $33M. Net income was $430M ($0.22 diluted EPS) vs $398M a year ago. The filing repeatedly references a pending transaction with Kimberly-Clark.
- Q3 net sales $3.886B, +3.2% YoY; organic sales +2.9% (volume +1.6%, price/mix +1.3%)
- Q3 operating income $706M, +12.2% YoY; operating margin 18.2%
- Q3 net income $430M ($0.22 diluted EPS) vs $398M ($0.21) a year ago
- Nine-month net income $1.36B, +19.3% YoY; restructuring expenses fell 20.1% to $163M
- Cash dividend of $0.42/share declared; accumulated deficit widened to $447M
Extended-hours last trade at $19.86, +1.53% vs regular close of $19.56, suggesting modestly positive reception to the Q3 beat on operating income and margin expansion.
Kenvue's Q3 shows accelerating operating leverage (18.2% margin) and declining restructuring costs, but the pending Kimberly-Clark deal overshadows standalone results.
Kenvue's 2.9% organic growth and 18.2% operating margin compare favorably in consumer health, where peers face private-label pressure. The pending Kimberly-Clark deal (noted throughout the filing) would reshape the competitive landscape.
Pending transaction with Kimberly-Clark introduces execution and integration risk. Tariff exposure flagged via refunds received on goods imported into the U.S.; input cost inflation from Middle East conflict cited. Foreign currency translation losses of $423M over nine months weigh on comprehensive income.